Facilities
ARCALIS delivers high-quality mRNA therapeutics and vaccines from Fukushima Minamisoma City to people all over the world.
ARCALIS has built a cGMP mRNA drug substance manufacturing facility in Minamisoma City in July 2023, aand is planning to commercialize the world's first approved product applying a self-amplifying mRNA technology vaccine from 2024.
The Drug Product facility is projected to be completed by 2027. At that time, we can offer one-stop manufacturing and release testing of mRNA therapeutics.
Minamisoma
320-20 Kawauchisako, Shimoota aza, haramachi, Minamisoma, Fukushima, Japan 975-0041
Google Map
Drug Substance (DS) Facility
In March 2022, construction of ARCALIS’ drug substance manufacturing plant began at the Shimoota Industrial Park in Minamisoma City (Fukushima Prefecture) and was completed on July 31, 2023.
The Minamisoma campus will also include a separate drug product manufacturing plant. Once completed in 2026,ARCALIS can offer one-stop manufacturing and release testing of mRNA therapeutics
Features
- Capable of manufacturing 5kg of mRNA per year
- Equipped with four manufacturing rooms with independent air handling to support four customer projects
Drug Product（DP）Facility
Start of construction in December 2023
Completion planned in February 2026
To be constructed with a subsidy from the government to strengthen the production of vaccines in Japan.
Features
- mRNA-LNP bulk fill and finish
Manufacturing, Technology Development（MD）Facility
Start of construction in April 2025
Completion planned in November 2027
To be constructed with a subsidy from the government to strengthen the production of vaccines in Japan.
Features
- LDNA Production, investigational drug production
- Technology development
Kashiwanoha
226-39 Wakashiba, Kashiwa-shi, Chiba 277-0871, Japan
Google MapKashiwanoha office
The Kashiwanoha office provides integrated drug discovery services and CMC development services. The three-story building is equipped with a manufacturing suite and a BSL (Biosafety level), 2-cell test laboratory on the first floor, offices on the second floor, and a physicochemical analysis and a quality testing laboratory on the third floor.
The Minamisoma campus will also include a separate drug product manufacturing plant. Once completed in 2026, (insert a space after the comma and a period at the end of the sentence.) Once completed in 2026,_ARCALIS can offer one-stop manufacturing and release testing of mRNA therapeutics.
Features
- Drug discovery services
- CMC development services※Quality testing equipment include a fragment analyzer, chromatograph system AKTA, UV spectrophotometer,pH meter, real-time PCR, capillary electrophoresis, and LC-MS/MS